Pipeline and Status

The chart below illustrates the status of GSNO Therapeutics’ pipeline programs for the drugs and disease models that have been completed to date. GTI-891.1 and GTI-850, both third-generation compounds, have been and are being studied in other animal models of disease. The drug candidates below are being tested in various disease models using many routes of administration. Safety studies have begun for GTI-891.1 and GTI-850. Because GTI-850 is more active against GSNOR in vitro and in vivo, it is our lead compound and has the most safety data, all of which show safety at high doses.

Drug Candidate	GSNOR Inhibition in Vitro	Indication	Route	Animal Studies
GTI-334.1	+	IPF Asthma Inflammation CVD NASH	PO PO IV/IP/PO IV IP	+ + + + +
GTI-850	+	Inflammation Inflammatory Bowel Diseases Autoimmune Conjunctivitis Aging in Monkeys (underway) ITP lifespan, mice (starting) CVD in rats (underway)	IV/PO/Top./IP PO Topical IV PO IV	+ + + + + +
GTI-889	+	Inflammation	IV/PO	+
GTI-890	+	Inflammation	IV/PO	+
GTI-891.1	+	Inflammation Oxidative Stress IPF NASH RA Inflammatory Bowel Diseases Heart Failure Stroke Neurodegeneration	IV/PO IP IP IP IP PO IP IV IP/Intravitreal	+ + + + + + + + +

Also of interest as strong GSNORis and IL-6 in vivo inhibitors: GTI-847, -894, and -895.

Review: GSNO Thera’s GSNOR Inhibition Technology

Regulating the Body’s Natural, Nitrosylation, Signal Transduction System for Multiple Therapies, and Safety.

In Evolution for 2-3 Billion Years. Only One Human GSNOR—Very Druggable Technology.

Small Molecule, Inexpensive Drugs To Synthesize, With Use and Composition of Matter IP.

Drugs Inhibit One Enzyme, GSNOR, With Multiple Therapeutic Effects: Inhibition of Inflammation, Oxidant Damage, Mitochondrial Damage, and Fibrosis (Reverses Existing Fibrosis)…

Multiple Mechanisms of Therapy Without Toxicity Enable Therapeutic Activity Across Multiple Disease Classes.

Concentrating on Inflammatory, Auto-Immune, Metabolic, Fibrotic, and Aging Diseases.

Safety: Large Toxic/Therapeutic Ratios and Lack of Off-Target Binding, i.e., Very Safe Activity in 26 Animal Models of Disease.

IP: One Issued Use Patent, Four Applications for Novel Compositions With International Filings. GSNO Therapeutics’ Drugs Could Fill a Large Pipeline.

Strong Management Team With Over 125 Years of Pharma Experience, From R&D to Preclinical, Clinical, and Business Development.

Ferid Murad, M.D., Ph.D., Is a Member of GSNO Therapeutics’ SAB; Ferid Won the Nobel Prize in 1998 for Discovering the Role of Nitric Oxide and Nitrosylation in Physiology; His Discovery Is One of the Foundations of GSNO Therapeutics’ Technology, and He Is a Great Addition to Our Team and a Strong Proponent of Our Technology; GSNO Therapeutics’ Technology Has Made Ferid’s Discovery Druggable in a Way It Wasn’t Before

This website uses cookies. We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Hours of Operation

Monday-Friday, 9 a.m.-5 p.m.

Phone

(301) 332-0942

mbradley@gsnothera.com

Intellectual Property

Pipeline & Status

Advisors & Collaborators

Publications